# Normal Saline Infusion for Stroke After Intravenous Thrombolysis

Study · id `cardio:ct-nct05993078` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05993078](<https://clinicaltrials.gov/study/NCT05993078>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05993078

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

## Technical summary

Registry record NCT05993078. Randomized; double masking; primary purpose treatment. Start 2023-09-01 (actual); primary completion 2024-12-20 (actual). Results posted on 2025-03-12.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 241 participants (enrolled count; ClinicalTrials.gov record NCT05993078, source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)
- Started: 2023-09-01 (actual) (ClinicalTrials.gov record NCT05993078, source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)
- Primary completion: 2024-12-20 (actual) (ClinicalTrials.gov record NCT05993078, source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)
- Completion: 2025-01-08 (actual) (ClinicalTrials.gov record NCT05993078, source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)
- Results first posted: 2025-03-12 (ClinicalTrials.gov record NCT05993078, source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05993078, source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05993078-2025-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Normal Saline Infusion for Stroke After Intravenous Thrombolysis
- Acronym: NS-STAR
- Condition: Brain Infarct
- Intervention (Drug): 0.9% NaCl 2000ml
- Intervention (Drug): 0.9% NaCl 200-400ml
- Lead sponsor: Tianjin Medical University General Hospital
- Lead sponsor class: OTHER
- Collaborator: Affliated Hospital of Jiujiang University
- Collaborator class: UNKNOWN
- Collaborator: Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Tianjin Medical University General Hospital (`cardio:org-tianjin-medical-university-general-hospital`)

## Provenance

Content hash: 50f659c79c01e68b67ca35f475b1186bac0b9646f9487d478b6418abbfc42b43
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
